Fig. 4: The persistence of CAR-T cells in the peripheral blood of patients enrolled in the clinical study (n = 21) was evaluated using qPCR and flow cytometry.
From: Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Peripheral blood mononuclear cells (PBMCs) were obtained from enrolled patients with R/R B-ALL. The patients underwent conditioning according to their disease burden. GC007F cells were infused after 24–48 h of conditioning. After GC007F cell infusion, PBMCs were collected to analyze cell pharmacokinetics on days 4, 7, and 10 and weeks 2, 4, 8 and 12. Three doses of GC007F cells (dose level (DL) 1 (green): 0.5 × 105 CAR+ T cells/kg, DL2 (blue): 1.0 × 105 CAR+ T cells/kg, and DL3 (red): 1.5 × 105 CAR+ T cells/kg) were used in this study. A The CAR copies/µg DNA of GC007F cells was detected using qPCR. B The numbers of CAR+ (GC007F) cells were detected using flow cytometry.
